Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and Fulvestrant in HR+/HER2- Breast Cancer
NCT05806047Phase 2Unknown
- Sponsor
- Fudan University
- Start
- May 2023
- Primary completion
- May 2024
01
Overview
A Phase 2 trial of tucidinostat in Hormone-Receptor-Positive Breast Cancer, sponsored by Fudan University. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT05806047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05806047.